• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

    7/17/23 8:45:25 AM ET
    $LGND
    $NOVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGND alert in real time by email

    – The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing –

    – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA –

    – Agreement provides a path forward for a product, if approved, to treat molluscum contagiosum, an unmet medical need –

    DURHAM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (NASDAQ:NOVN) and its wholly owned subsidiary, EPI Health, LLC (collectively, "the Company" or "Novan"), today announced that it has entered into a stalking horse asset purchase agreement ("APA") with Ligand Pharmaceuticals, Inc. ("Ligand") (NASDAQ:LGND) prior to filing voluntary petitions for relief under chapter 11 of title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the "Chapter 11 Case"). The Company continues to operate its business as a "debtor-in-possession" ("DIP") under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. The Company also entered into a secured DIP credit facility with Ligand in the principal amount of $15.0 million.

    The APA governs the sale of substantially all the assets of the Company for $15 million to be paid in cash at closing. The cash payable at closing will be reduced dollar-for-dollar by the outstanding balance of the DIP credit facility which will be repaid at closing. The transaction will be subject to approval by the Bankruptcy Court and compliance with agreed upon and Bankruptcy Court-approved bidding procedures allowing for the submission of higher or otherwise better offers, and other agreed-upon conditions.

    In addition, on July 14, 2023, the Company entered into a bridge loan with Ligand for the principal amount of $3.0 million. This pre-petition loan provided needed working capital to the Company for general corporate purposes and is secured by the assets of the Company. The pre-petition bridge loan will be rolled into the DIP credit facility after Bankruptcy Court approval of the DIP credit facility.

    As the Chapter 11 Case progresses, the Company plans to continue to work with the FDA to progress towards potential approval of berdazimer gel, 10.3% (SB206), with a PDUFA goal date of January 5th, 2024. In the second quarter of 2023, the Company received its mid-cycle review communication from the FDA, in addition to the manufacturing facility's pre-approval inspection and establishment inspection report.

    Novan has engaged Raymond James & Associates to advise on its strategic options, including the process to sell its assets in connection with the Chapter 11 Case. As previously disclosed, the Company has been pursuing financing and strategic alternatives as well as taking measures to conserve cash. The board of directors of the Company made the decision to commence the Chapter 11 Case, with Ligand as a stalking horse bidder, after careful review of such alternatives, after considering factors such as the Company's challenging financial circumstances and the challenging market climate for similarly situated companies and upon consultation with the Company's professional advisors.

    The above description of the APA and the DIP credit facility and the transactions contemplated by those documents, including the sale, does not purport to be complete. Please refer to the Company's Form 8-K, filed with the U.S, Securities and Exchange Commission on July 17, 2023, for the full text of the APA and the DIP credit facility.

    Additional information about the Chapter 11 Case, including access to Bankruptcy Court documents, is available online at www.kccllc.net/novan.

    About Novan

    Novan, Inc. is a medical dermatology company focused on developing and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. The U.S. Food and Drug Administration ("FDA") accepted for filing Novan's New Drug Application ("NDA") seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum. The Company also has a pipeline of potential product candidates using its proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

    Cautionary Statements

    The Company cannot assure that holders of the Company's common stock will receive any payment or other distribution on account of those shares following the Chapter 11 Case. As currently contemplated under the APA, stockholders will not receive any payment or other distribution, and any payment or distribution to stockholders would be dependent on the results of the sale process, which are speculative. The Company cautions that trading in the Company's common stock during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. Trading prices for the Company's common stock may bear little or no relationship to the actual recovery, if any, by holders of the Company's common stock in the Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its common stock.

    Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "target," "anticipate," "may," "plan," "potential," "will," "look forward to" and similar expressions, and are based on the Company's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements related to the potential FDA approval and the timing thereof of the Company's NDA for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum, along with the Company's plans to support the approval process; the potential therapeutic value of the Company's products and product candidates; the Company's plans to sell its assets pursuant to Chapter 11 of the U.S. Bankruptcy Code and the timing of such sales and ability to satisfy closing conditions; the Company's intention to continue operations during the Chapter 11 Case; the Company's belief that the sale process will be in the best interest of the Company and its stakeholders; and other statements regarding the Company's strategy and future operations, performance and prospects. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the Company's expectations, including, but not limited to, the risks associated with the potential adverse impact of the Chapter 11 filings on the Company's results of operations; changes in the Company's ability to meet its financial obligations during the Chapter 11 process, to comply with the terms of the APA and the DIP credit facility and to maintain contracts that are critical to its operations; the outcome and timing of the Chapter 11 process and any potential asset sale; the effect of the Chapter 11 filings and any potential asset sale on the Company's relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the potential asset sale; uncertainty regarding obtaining Bankruptcy Court approval of a sale of the Company's assets or other conditions to the potential asset sale, including the bidding procedures agreed by the parties; risks related to the regulatory approval process, which is lengthy, time-consuming and inherently unpredictable, including the risk that the FDA will not agree with the Company's approach in its NDA submission for berdazimer gel, 10.3% (SB206) for molluscum or any future NDA submission or that the Company's product candidates may not be approved or that additional studies may be required for approval or other delays may occur; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the twelve months ended December 31, 2022, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and the Company disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

    CONTACT:

    Jenene Thomas

    JTC Team, LLC

    833-475-8247

    [email protected]



    Primary Logo

    Get the next $LGND alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LGND
    $NOVN

    CompanyDatePrice TargetRatingAnalyst
    Ligand Pharmaceuticals Incorporated
    $LGND
    4/10/2025$143.00Buy
    Stifel
    Ligand Pharmaceuticals Incorporated
    $LGND
    10/3/2024$135.00Outperform
    Oppenheimer
    Ligand Pharmaceuticals Incorporated
    $LGND
    7/30/2024$130.00Outperform
    RBC Capital Mkts
    Ligand Pharmaceuticals Incorporated
    $LGND
    2/22/2022$180.00 → $130.00Buy
    Benchmark
    Ligand Pharmaceuticals Incorporated
    $LGND
    2/18/2022$185.00 → $165.00Overweight
    Barclays
    Novan Inc.
    $NOVN
    9/24/2021$28.00 → $24.00Buy
    HC Wainwright & Co.
    Ligand Pharmaceuticals Incorporated
    $LGND
    9/22/2021$174.00 → $180.00Overweight
    Barclays
    Ligand Pharmaceuticals Incorporated
    $LGND
    7/30/2021$200.00 → $190.00Buy
    Roth Capital
    More analyst ratings

    $LGND
    $NOVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Participate in May Investor Conferences

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual). Management will participate in a fireside chat on May 13, 2025 at 3:30 p.m. ET and be available for one-on-one meetings.RBC Capital Markets Global Healthcare Conference (New York). Management will participate in a fireside chat on May 20, 2025 at 2:05 p.m. ET and be available for one-on-one meetings.Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 28, 2025.

      5/1/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

      JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S. & Canada)  (646) 307-1963 (International)  Conference ID 3661098   Webcast: Live and replay webcasts of the call are available here.    About Ligand PharmaceuticalsLiga

      4/24/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sabba Stephen L exercised 2,406 shares at a strike of $52.30, increasing direct ownership by 8% to 32,584 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      4/16/25 9:34:19 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CLO & Secretary Reardon Andrew was granted 6,415 shares, increasing direct ownership by 23% to 34,783 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      3/6/25 6:55:43 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Espinoza Octavio sold $575,148 worth of shares (5,000 units at $115.03) and was granted 7,484 shares, increasing direct ownership by 10% to 26,363 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      3/6/25 6:55:23 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Ligand Pharma with a new price target

      Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00

      4/10/25 12:42:08 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Ligand Pharma with a new price target

      Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00

      10/3/24 7:34:05 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ligand Pharma with a new price target

      RBC Capital Mkts initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $130.00

      7/30/24 6:24:41 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated

      SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      11/1/24 4:07:52 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ligand Pharmaceuticals Incorporated

      SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      2/14/24 6:26:25 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      2/13/24 5:08:05 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Financials

    Live finance-specific insights

    See more

    $LGND
    $NOVN
    SEC Filings

    See more

    $LGND
    $NOVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

      JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S. & Canada)  (646) 307-1963 (International)  Conference ID 3661098   Webcast: Live and replay webcasts of the call are available here.    About Ligand PharmaceuticalsLiga

      4/24/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

      Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of

      3/31/25 7:30:00 AM ET
      $LGND
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      5/8/25 7:06:37 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ligand Pharmaceuticals Incorporated

      DEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      4/22/25 4:09:42 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ligand Pharmaceuticals Incorporated

      DEF 14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      4/22/25 4:07:56 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Davis Todd C bought $243,480 worth of shares (2,500 units at $97.39), increasing direct ownership by 2% to 123,010 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      8/9/24 5:52:17 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Davis Todd C bought $237,529 worth of shares (4,000 units at $59.38), increasing direct ownership by 6% to 73,090 units

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      9/25/23 4:44:43 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

      WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

      10/17/24 7:30:00 AM ET
      $LFCR
      $LGND
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OmniAb Announces Completion of Spin-Off and Business Combination

      Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

      11/1/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum

      – Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received conditional acceptance from U.S. FDA for use of KINSOLUS™ as brand name for SB206, if approved – – First New Drug Application (NDA) remains on target with submission expected in Q3 2022 – DURHAM, N.C., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced the appointment of Brian M. Johnson as its Chief Commercial Officer. Additionally, the Company received notice that the U.S. Food and Drug Administration (FDA) has conditionally accepted KI

      11/2/21 8:30:00 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care